ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary selective organ targeting (SORT) LNP delivery platform, today announced that Company leadership will present virtually at the 40th Annual J.P. Morgan Healthcare Conference.
-
Presentation details:
Date: Thursday, January 13, 2022
Time: 9:00 a.m. – 9:25 a.m. ET
Presenter: David Lockhart, Ph.D., President & Chief Scientific Officer
The presentation will be accessible to registered conference attendees.
About ReCode Therapeutics
ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its proprietary LNP platform and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220110005241/en/
Contacts
Media Contact:
Will Zasadny
Canale Communications, Inc.
Will.zasadny@canalecomm.com
(619) 961-8848
Investor Contact:
Sarah McCabe
Stern Investor Relations
sarah.mcCabe@sternir.com
IR@recodetx.com
